# IO Resistant Squamous and Nonsquamous NSCLC FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/io-resistant-squamous-and-nonsquamous-nsclc

> 2 upcoming FDA catalysts in IO Resistant Squamous and Nonsquamous NSCLC: TAK-928 (TAK) on November 2028 (primary completion); TAK-928 (TAK) on Nov 2028 to Feb 2029 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 2028 | [TAK-928 primary completion](https://sec-api.dev/pdufa/tak-928) | TAK | IO Resistant Squamous and Nonsquamous NSCLC | scheduled | "NCT07217301 (A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217301)) |
| Nov 2028 to Feb 2029 | [TAK-928 topline data readout](https://sec-api.dev/pdufa/tak-928) | TAK | IO Resistant Squamous and Nonsquamous NSCLC | scheduled | "NCT07217301 (A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217301)) |

## Drugs

- [TAK-928](https://sec-api.dev/pdufa/tak-928) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/io-resistant-squamous-and-nonsquamous-nsclc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IO Resistant Squamous and Nonsquamous NSCLC FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/io-resistant-squamous-and-nonsquamous-nsclc

```bibtex
@misc{secapidev_indications_io_resistant_squamous_and_nonsquamous_nsclc_20261116,
  title        = {IO Resistant Squamous and Nonsquamous NSCLC FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/io-resistant-squamous-and-nonsquamous-nsclc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_io_resistant_squamous_and_nonsquamous_nsclc_20261116","title":"IO Resistant Squamous and Nonsquamous NSCLC FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/io-resistant-squamous-and-nonsquamous-nsclc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
